(NasdaqGM:EH), NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of EHang Holdings Limited (“EHang” or the “Company”) (NASDAQ: EH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether EHang and certain of its officers and/or directors have […]
(NYSE:SKLZ), NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Skillz Inc. (“Skillz” or the “Company”) (NYSE: SKLZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Skillz and certain of its officers and/or directors have engaged
(NYSE:CYBN), NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Cybin and certain of its officers and/or directors have engaged
(NYSE:FI), NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Fiserv, Inc. (“Fiserv” or the “Company”)(NYSE: FI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their
(NASDAQ:AGIO), NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Agios and certain of its officers and/or directors have
(NasdaqGM:QMCO), NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Quantum Corporation (“Quantum” or the “Company”)(NASDAQ: QMCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their
(NYSE:TROX), NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Tronox Holdings Plc (“Tronox” or the “Company”) (NYSE: TROX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to
(NASDAQ:SMLR), NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Semler Scientific, Inc. (“Semler” or the “Company”) (NASDAQ: SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to
(NasdaqGM:LFMD), NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or the “Company”)(NASDAQ: LFMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their
(NYSE:AI), NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against C3.ai, Inc. (“C3” or the “Company”) (NYSE: AI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include